


Attorney Docket No. 5218-39B



11/03/05
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al.
Application No.: 09/525,797
Filed: March 15, 2000
For: Method of Treating Endothelial Injury

Confirmation No.: 9917
Group Art Unit: 1642
Examiner: Susan NMN Ungar

Date: October 31, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(c)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004. This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

In accordance with the requirements of 37 C.F.R. § 1.97(c)(2), a check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. This amount is believed to be correct. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Respectfully submitted,

Shawna Cannon Lemon
Registration No. 53,888

11/03/2005 JBALINAN 00000013 09525797

01 FC:1806

180.00 OP

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 31, 2005.

Susan E. Freedman


Date of Signature: October 31, 2005

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of

*Complete if Known*

Application Number	09/525,797
Filing Date	March 15, 2000
First Named Inventor	Athanasius Anagnostou
Group Art Unit	1642
Examiner Name	Susan Nmn Ungar
Attorney Docket Number	5218-39B

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	US-				
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Carlini et al. "Recombinant Human Erythropoietin (rHuEPO) Increases Endothelin-1 Release by Endothelial Cells" <u>Kidney International</u> 43: 1010-1014 (1993)	
	2.	De Vos et al. "Endothelial cell effects of cytotoxics: balance between desired and unwanted effects" <u>Cancer Treat Rev</u> 30(6): 495-513 (Oct. 2004)	
	3.	Hockel et al. "Therapeutic Angiogenesis" <u>Arch Surg</u> 128: 423-429 (1993)	
	4.	M. Cazzola; "Erythropoietin: biology and clinical applications"; <u>Trends in Experimental and Clinical Medicine</u> , 3:344-361 (1993)	
	5.	Miller et al. "Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated Anemia" <u>J Natl Cancer Inst</u> 84(2): 98-103 (1992)	
	6.	Rubins "Response to Treatment with Human Recombinant Erythropoietin" <u>Annals of Internal Medicine</u> 122(9): 676-677 (1995)	
	7.	Silvestris et al. "Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma" <u>Ann Hematol</u> 70(6): 313-318 (1995)	
	8.	Sungur "Renal Cell Carcinoma and Erythropoietin" <u>Annals of Internal Medicine</u> 123(9): 732-733 (1995)	

Examiner Signature

/Karen A. Canella, Ph.D./

Date Considered

08/18/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/